Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 602

1.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, Philippe N, Thomas X, Dombret H, Preudhomme C.

Cancer. 2009 Aug 15;115(16):3719-27. doi: 10.1002/cncr.24442.

2.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

3.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.

J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.

PMID:
20439648
4.

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group.

Blood. 2009 May 7;113(19):4505-11. doi: 10.1182/blood-2008-10-183392. Epub 2009 Feb 12.

5.

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 Feb 1;28(4):578-85. doi: 10.1200/JCO.2009.23.0342. Epub 2009 Dec 28.

PMID:
20038731
6.

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, Tang JL, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

Blood. 2010 Jun 24;115(25):5222-31. doi: 10.1182/blood-2009-12-259390. Epub 2010 Apr 5.

7.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
8.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

N Engl J Med. 2008 May 1;358(18):1909-18. doi: 10.1056/NEJMoa074306.

9.

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S, Nibourel O, Pautas C, Reman O, Thomas X, Gardin C, Terré C, Castaigne S, Preudhomme C, Dombret H.

Blood. 2009 May 21;113(21):5090-3. doi: 10.1182/blood-2008-12-194704. Epub 2009 Mar 16.

10.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
11.

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.

Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, Willasch A, Kaspers GJ, Trka J, Baruchel A, de Graaf SS, Creutzig U, Pieters R, Reinhardt D, Zwaan CM.

Blood. 2009 Jun 4;113(23):5951-60. doi: 10.1182/blood-2008-09-177949. Epub 2009 Jan 26.

12.

Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.

Colovic N, Tosic N, Aveic S, Djuric M, Milic N, Bumbasirevic V, Colovic M, Pavlovic S.

Ann Hematol. 2007 Oct;86(10):741-7. Epub 2007 Jun 20.

PMID:
17579862
13.

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B.

Blood. 2005 Dec 1;106(12):3733-9. Epub 2005 Aug 2.

14.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
15.

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.

Steudel C, Wermke M, Schaich M, Schäkel U, Illmer T, Ehninger G, Thiede C.

Genes Chromosomes Cancer. 2003 Jul;37(3):237-51.

PMID:
12759922
16.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C.

J Clin Oncol. 2010 Aug 10;28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12.

PMID:
20625116
17.

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K.

J Clin Oncol. 2004 Feb 15;22(4):624-33. Epub 2004 Jan 15.

PMID:
14726504
18.

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.

Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, Fricke HJ, Höffken K, Wedding U.

Eur J Haematol. 2008 Mar;80(3):208-15.

PMID:
18081718
19.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H.

Blood. 2005 Dec 1;106(12):3740-6. Epub 2005 Jul 28.

20.

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B, Valk PJ.

Blood. 2005 Dec 1;106(12):3747-54. Epub 2005 Aug 18.

Supplemental Content

Support Center